Back to search results

VX-272 Safety Study in Healthy Adults

This study is testing a new medication called VX-272, given as a liquid you drink, to see how safe it is and how your body handles it. It's also comparing VX-272 to a placebo (an inactive substance that looks like the study drug). The main goal is to check for any side effects or serious problems. We're looking for healthy adults between 18 and 55 years old, who weigh more than 50 kg (about 110 pounds) and have a body mass index (BMI) between 18.0 and 32.0. This study is for people who do not have cystic fibrosis, but it is being done to gather information that may eventually help people with cystic fibrosis. We plan to include about 128 participants.

Study design
This is an interventional study, meaning participants will receive either VX-272 or a placebo. It aims to enroll 128 healthy participants.
What's involved
Participants will be monitored for safety and side effects from the day before the first dose up to 34 or 66 days after starting the study.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety and tolerability for up to 66 days after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07437105

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants

Recruiting
PHASE1Ages 18–55InterventionalTreatment
Vertex Pharmaceuticals Incorporated
~128 participants
Updated 2026-03-31 on ClinicalTrials.gov
What's tested:VX-272Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over From Day -1 up to Day 34
+1 more outcome measured

Conditions

Cystic Fibrosis

Explore related trials

Cystic Fibrosis

Where it's being run

1 sites across 1 states
Arizona1

Who to contact

Medical Information
[email protected]
617-341-6777
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
A total body weight of more than (\>) 50 kg
Male and Female participants of non-childbearing potential

Exclusion

History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
Any condition possibly affecting drug absorption

What this trial measures

  • Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)From Day -1 up to Day 34
  • Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)From Day -1 up to Day 66